Related Experiment Video

Updated: Jun 4, 2025

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
06:46

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

213

Breast cancer treatment delay and the Hispanic paradox: A SEER database analysis

Estefania Roldan-Vasquez1, Samir Mitri2, Kristen D Brantley3

  • 1Breast Surgical Oncology, Department of Surgery. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

American Journal of Surgery
|December 27, 2024
PubMed

Insights

Hispanic breast cancer patients face longer wait times for treatment, increasing their risk. Despite delays, their survival within that group was better, highlighting healthcare inequities. Targeted interventions are crucial for equitable care.

Area of Science:

  • Oncology
  • Health Services Research
  • Health Equity

Background:

  • Breast cancer (BC) is the most prevalent cancer among women in the United States.
  • Significant knowledge gaps persist regarding healthcare inequities faced by Hispanic BC patients.
  • This study aimed to assess BC characteristics and treatment patterns within this demographic.

Purpose of the Study:

  • To evaluate healthcare disparities in breast cancer care for Hispanic patients.
  • To analyze the association between Hispanic ethnicity and time to treatment (TT).
  • To determine the impact of treatment delay on cancer-specific survival among Hispanic and non-Hispanic white (NHW) women.

Main Methods:

  • Utilized data from the SEER Database (2018-2020) for invasive BC cases.
  • Compared Hispanic and NHW women, analyzing time from diagnosis to treatment (TT).
  • Employed logistic regression, Kaplan-Meier curves, and Cox regression models to assess TT delays and survival outcomes.

Main Results:

  • Hispanic patients constituted 16.5% of the 135,690 BC cases studied.
  • Median TT was significantly longer for Hispanics (1.5 months) compared to NHW (1.22 months) (p < 0.001).
  • Hispanics had 2.47 times higher odds of delayed TT (>3 months). Delayed TT worsened survival, but Hispanics with delayed TT showed better survival (HR: 0.52).

Conclusions:

  • Healthcare disparities for Hispanic breast cancer patients are evident.
  • Targeted interventions and public health initiatives are necessary to ensure equitable care.
  • Further research is needed to understand the factors contributing to these survival differences within delayed treatment groups.
Abstract

More Related Videos

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases07:41

Performing Data Mining And Integrative Analysis Of Biomarker in Breast Cancer Using Multiple Publicly Accessible Databases

Published on: May 17, 2019

8.9K
A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting14:43

A Novel Method for Involving Women of Color at High Risk for Preterm Birth in Research Priority Setting

Published on: January 12, 2018

11.7K

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
149
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
87
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
94
Truncation in Survival Analysis01:09

Truncation in Survival Analysis

Truncation in survival analysis refers to the exclusion of individuals or events from the dataset based on specific criteria related to the time of the event. This exclusion can happen in two primary forms: left truncation and right truncation.
Left truncation occurs when individuals who experienced the event of interest before a certain time are not included in the study. This is often due to a "delayed entry" into the study where only those who survive until a certain entry point are...
156